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Abstract 
 
Glucocorticoid hormones play vital roles in regulating diverse biological process in health 
and disease. Tissue levels are regulated by enzymes which activate and inactivate hormones. 
The enzyme, 11β-hydroxysteroid dehydrogenase type 1, in particular, has been identified as a 
potential drug target; inhibiting this enzyme attenuates glucocorticoid action by lowering 
local levels of active hormone.  
 
A variety of mass spectrometric approaches have been developed to characterise the enzyme 
in vivo. Endogenous glucocorticoids and their metabolites can be profiled in urine by gas 
chromatography mass spectrometry and circulating steroids are now more commonly 
quantified by liquid chromatography tandem mass spectrometry. Tracer dilution studies have 
allowed rates of generation of glucocorticoids by the enzyme to be distinguished from 
hormone generated directly by the adrenal glands and, in combination with arterio-venous 
sampling, rates of production by specific tissues have been quantified. This has allowed the 
contribution of liver, adipose, muscle and brain to cortisol production in metabolic disease 
and hence drug targets prioritised. Most recently mass spectrometry imaging in combination 
with on-tissue derivatisation has been developed to profile keto-steroids in tissue sections, 
allowing molecular maps to be generated across complex tissues, where regional functions are 
important.  
 
The review provides a synopsis of how measurement of steroids by mass spectrometry has 
evolved to provide insight into the dynamic turnover of glucocorticoids in vivo, highlighting 
the milestones that have advanced the field and identifying the remaining challenges for 
researchers, in terms of analytical chemistry and endocrine physiology and biochemistry. 
Glucocorticoids: tissue specific metabolism and actions 
 
Glucocorticoid hormones regulate diverse physiological functions, including immune, 
metabolic and stress responses, through their actions on nuclear hormone receptors (mainly 
glucocorticoid and mineralocorticoid receptors). Glucocorticoid biosynthesis happens 
principally in the adrenal gland through a steroidogenic cascade, triggered by activation of the 
hypothalamic-pituitary-adrenal (HPA) axis. This negative feedback loop tightly regulates 
concentrations of circulating steroids, but active hormone concentrations are also controlled 
within tissues, where distinct enzymes inactivate and activate steroids, e.g. 11β-
hydroxysteroid dehydrogenases (11βHSDs), 5α and 5β-reductases, 3αHSD and CYP3A4 
(catalysing 6-hydroxylation) [1] (Figure 1). 
 
There are two isozymes of 11βHSDs [2]. Type 2 inactivates 11β-hydroxy-glucocorticoids 
forming inert 11-ketosteroids (cortisol and cortisone respectively in humans) and is present 
mainly in kidney [3;4]. It also plays a vital role in the placenta where it protects the foetus 
from exposure to endogenous, maternal glucocorticoids [4], although is a less efficient barrier 
to exogenous steroids, such as dexamethasone [5;6].  
 
In contrast 11βHSD1 regenerates active 11-hydroxy from 11-keto-glucocorticoids [7], and 
has become an attractive therapeutic target to attenuate glucocorticoid action in metabolic 
disease and cognitive decline [2]. In defining 11βHSD1 as a therapeutic target, it is important 
to understand the contribution made by the enzyme to active hormone levels in distinct tissues 
(e.g. liver, brain, adipose), where dysregulation may arise. Approaches to measure 
glucocorticoid production rates and tissue specific metabolism by 11βHSD1 have evolved, 
driven largely by advancing mass spectrometric (MS) tools. MS offers superior analytical 
specificity to immunoassays and indeed a recent Endocrine Society statement has indicated 
the need for MS analysis of steroid hormones for acceptance for publication [8]. This mini-
review summarises how understanding of glucocorticoid physiology and pathophysiology has 
been illuminated by the use of MS. 
 
A. Mass spectrometry applied to steroid biochemistry 
For steroids to be detected by MS, they must be ionised, typically forming singly charged ions, 
and subsequently detected by their mass to charge ratios (m/z). For quantitative MS, the mass 
analyser is commonly a quadrupole, ideal for its fast scanning rate and wide dynamic range, 
allowing multiple species of low and high abundance to be measured concomitantly. Initially 
single quadrupole systems were used, monitoring the most abundant and discriminatory ions 
from the molecule’s mass spectrum, but more recently tandem MS has become the method 
choice. By measuring the transition of a precursor to product ion, following fragmentation in 
the collision cell, specificity and sensitivity are improved, since background noise is 
minimised. Accurate mass systems are now coming on-line for quantitation, with some 
researchers asserting similar quantitative performance, with improved specificity [9]. 
Accurate mass systems enable the potential for non-targeted analysis in conjunction with 
targeted quantitation. 
 
Conventionally liquid extracts of samples are introduced into the MS via a gas or liquid 
chromatograph (GC or LC). GC-MS has underpinned many pivotal studies of glucocorticoid 
metabolism, with Shackleton leading the field [10;11]. Analytes are deposited onto a column 
lined with a chemically defined stationary phase. The column is heated and sample 
components volatilise at their boiling point into the carrier gas at distinct temperatures. They 
are detected by the MS, generating a mass chromatogram. GC-MS therefore allows 
identification of steroids by their retention times, m/z ratios and fragmentation patterns. To 
minimise polar interactions with the stationary phase, compounds are commonly derivatised 
to disguise hydrogen bonding sites. Methoxime-trimethyl silyl derivatives are the most 
common, offering characteristic fragment ions with loss of m/z 31 and 90. Peaks elute rapidly 
from GC columns over narrow time windows, well suited to resolve steroid isomers. GC-MS 
and now MS/MS is an excellent analytical approach to define complex steroid mixtures as has 
been exemplified in the “steroidomic” approach  characterising adrenal malignancies [12]. 
 
GC instruments were interfaced to MS before LC, due to facile removal of the carrier gas 
eluting from the column. The interface between LC and MS took longer to develop, through 
difficulties in desolvating the mobile phase. However ion transfer into the LC-MS/MS 
systems is now efficient, and routinely used for steroid analysis e.g. in Clinical Biochemistry 
[13]. Although small molecular weight drugs may be relatively easily analysed, steroids prove 
more challenging due to their resistance to ionisation and susceptibility to matrix interference, 
so called “ion suppression”. GC commonly employs “electron impact” ionisation, whereby a 
beam of highly energised electrons break covalent bonds readily generating ions. In contrast 
softer “electrospray” with LC-MS/MS, relies on spontaneous ionisation. Glucocorticoids lack 
readily ionisable groups and therefore ionisation efficiency is poor. Alternative ionisation 
modes such as atmospheric pressure chemical ionisation (APCI) can be helpful but reduced 
steroids (e.g. A-ring reduced metabolites) still respond poorly. LC-MS/MS is mainly used for 
measuring selected plasma steroids, whereas reduced metabolites are still preferentially 
determined by GC-MS(MS). Derivatisation, in conjunction with LC, can enhance ion 
abundance throughout introduction of charged or chargeable groups improving sensitivity and 
broadening scope; for example use of Girard reagents for testosterone analysis [14], an 
approach which has also been applied  for oxysterol profiling [15]. Sensitivity of analysis of 
estrogens benefits similarly following derivatisation [16]. 
 
B: How MS can be applied to measure tissue-specific glucocorticoid metabolism 
Analysis by both GC-MS(MS) and LC-MS/MS have underpinned studies characterising 
glucocorticoid metabolism in health and disease. Features of glucocorticoid excess in 
Cushing’s Syndrome, resemble those of idiopathic Metabolic Syndrome (central obesity, type 
2 diabetes, hypertension, dyslipidaemia), leading to the hypothesis that attenuating 
glucocorticoid action by inhibiting 11βHSD1 may be beneficial in metabolic disease [2]. 
Urinary glucocorticoid profiling by MS is widely used to assess integrated whole body daily 
glucocorticoid production rates. In humans, cortisol and ~10 of its metabolites [10] are 
detected and the approach can be extended to include androgens, progestogens and 
mineralocorticoids, offering insights into the balance of synthetic and metabolic pathways of 
adrenal hormones.  
 
The ratio of the main urinary cortisol metabolites (αTHF and βTHF) to those of cortisone 
(βTHE) is commonly reported as an index of the balance of whole body activities of the types 
1 and 2  isozymes of 11βHSD [17]; changes in the activities or either enzyme can alter the 
ratio, seen when 11βHSD1 or 2 are disrupted genetically or by pharmacological/xenobiotic 
inhibitors [18-21]. 5α and 5β-Reduced metabolites of cortisol but only 5β-reduced 
metabolites of cortisone are used in the calculation, and thus the ratio may be skewed by 
differential dysregulation of either 5α or 5β-reductases, e.g. in obesity [22;23] and liver 
disease [24;25]. Therefore, although this index is reported widely, confounders in the measure 
have contributed to conflicting and inconsistent data e.g. in obesity [23;26;27] . 
 
Therefore, with 11βHSD1 becoming a potential pharmaceutical target, it became important to 
devise ways to measure 11βHSD1 independently of other enzymes. The following approaches 
reported by Rask et al [26;28] yielded early novel insights into tissue-specific dysregulation 
of 11βHSD1 in liver and adipose in obesity, but caveats persisted over the interpretation of 
the data. The velocity of 11βHSD1 in adipose biopsies ex vivo may be assessed in conjunction 
with transcript levels. These data reflect protein and transcript amounts, but the actual rate of 
generation of cortisol in vivo is dependent on available substrate concentration; circulating 
cortisone concentrations are ~100 nM [29], considerably lower than the low micromolar Km 
for reduction. The activity of the hepatic enzyme was assessed by formation of cortisol by 
first pass hepatic metabolism of oral cortisone. This may be confounded by variable 
gastrointestinal absorption, and changes the activities of other hepatic metabolic enzymes [22]. 
For example, A-Ring reductases operate within similar kinetic ranges [30;31], and therefore 
compete with 11βHSD1 for substrates. Cyp3A4, generating 6β-hydroxortisol, is highly 
variable in its activity between people, modified by genetics, nutrition and prescription drugs 
[32]. 
 
A major step forward in the field came with in vivo tracer dilution studies of regeneration of 
cortisol by 11βHSD1. Tracer dilution [33] has been used commonly to assess rates of fuel 
production and utilisation e.g. glucose and amino acids/proteins. The endogenous pool of 
bioanalyte, the “tracee”, is enriched to a small degree with stable-isotope labelled tracer 
administered, usually as a fixed rate infusion. At steady state, concentrations of compounds in 
the blood are proportional to their rates of production, assuming equivalent clearance. 
Endogenous tracee production rates may be calculated from the relative abundance of the 
tracee and tracer measured by their distinct masses by MS in blood or other biomatrices. 
 
Early developments in the field of tracer kinetics relied on radioactively labelled tracers [34] 
and revealed that important information could be gleaned by careful consideration of the site 
of the radiolabel within the molecule. Tritiated tracers labelled at the 11α position were 
converted to unlabelled cortisone upon exposure to 11βHSD2 and recycled by addition of a 
proton to unlabelled cortisol. In contrast, cortisol tracers labelled elsewhere form labelled 
cortisone, which is recycled back to the original labelled cortisol, under-estimating clearance 
[34]. Measuring differential clearance between these types of tracer gave the first insight into 
potential approaches to achieve a specific measure of 11βHSD1 activity.  Aside from safety 
reasons, radiotracers are not ideal because quantitation achieved by the abundance of 
radionuclide, may be confounded by labelled metabolites.   
 
Safer stable-isotope labelled tracers have now been developed to quantify cortisol kinetics 
[29;35]. In particular “D4-cortisol” or 9,11α,12,12 [2H4]-cortisol has allowed investigation of 
the contribution of 11βHSD1 to cortisol production [29].  When administered in vivo D4-
cortisol loses its 11α-deuterium through metabolism by 11βHSD2 generating 9,12,12 [2H3]-
cortisone, a substrate for 11βHSD1 (Figure 2) [35]. Reduction incorporating a proton 
generates 9,12,12 [2H3]-cortisol (D3-cortisol), which can be distinguished by mass from 
cortisol and the original tracer. Similar to 11α-tritiated cortisol,  the rate of clearance of D4-
cortisol is more rapid than that of cortisol or other tracers [29], since D4-cortisol cannot be 
regenerated by 11βHSD1. The rate of generation of D3-cortisol by 11βHSD1 can be assessed 
by comparing its steady state levels to those of infused D4-cortisol. 
 
This approach measures both cortisol and D3-cortisol production rates. Cortisol production 
rates incorporate steroid generated by adrenal synthesis and by 11βHSD1. Indeed 11βHSD1 
makes a considerable contribution to the overall total [36]. D3-Cortisol generation reflects 
11βHSD1 alone and the rates may be adjusted for D3-cortisone substrate concentrations, 
commonly below the Km of the enzyme. In typical experimental protocols the endogenous 
pool of cortisol is enriched to ~10-20% with D4-cortisol to allow easy analytical detection. 
Lower enrichments would be desirable to limit suppression of the HPA axis and disruption of 
the endogenous pool [33] and this may become possible as new instrumentation with 
improved sensitivity becomes available.   
 
Using the D4-cortisol tracer has opened doors to measures of whole body generation of 
cortisol and D3-cortisol first and foremost in metabolic disease. Whole-body generation of 
cortisol by 11βHSD1 does not appear increased in obesity, at least until it is more severe [37-
39]. Given previous interest in tissue-specific dysregulation of the enzyme, the tracer 
approach was soon applied in combination with arterio-venous (AV) sampling to assess the 
contribution of 11βHSD1 in specific tissues; the splanchnic bed [40;41], liver [40], sub-
cutaneous and visceral adipose [36;39;40;42;43], heart [44], muscle [43] and brain [45]. The 
vast majority of whole body cortisol generation may be accounted for by the splanchnic bed 
[36;39;40;42], but there is discernable production across the sub-cutaneous adipose beds and 
muscle [36;43]. Measurement across the splanchnic bed reflects not only the liver but also 
visceral adipose tissue. Portal sampling, applied in conjunction with tracers, in humans [36] 
and dogs [42] suggests that most if not all of the splanchnic production is by liver. A less 
invasive approach to discriminate hepatic metabolism has been to combine AV tracers with 
the oral cortisone “First pass metabolism” test [46]. By assessing rate of cortisol production 
from cortisone by tracer dilution [36;39], it is possible to overcome a previous critique that 
the test is influenced by differential clearance [39]. These techniques have been applied to the 
study of  nutrition and weight loss [47-49] and insulin sensitising drugs [50] on cortisol 
production by 11βHSD1 and helped to quantify the enzyme target for pharmacotherapy.  
 
Finally, combining D4-cortisol infusions with a further D2-cortisone tracer allows 
concomitant quantitation of dehydrogenation of cortisol [43]. This is largely believed to be 
through 11βHSD2, however debate exists over whether 11βHSD1 operates in a reversible 
capacity in vivo [43;51] and whether this might be manipulated by altering co-factor 
availability. An example of use of the combined tracer approach was in the demonstration of 
impaired clearance of cortisol in subjects with critical illness [52]. However the enzyme 
involved in dehydrogenation could not be confirmed by these types of tracer dilution studies 
alone. 
 
C: What MS holds for the future 
 
The techniques described have greatly advanced our understanding of 11βHSD1 biology but 
questions still remain about how the enzyme influences receptors within sub-regions of 
complex tissues; functional regions of the brain and kidney or within cell sub-populations 
within tissues, e.g. inflammatory cells within adipose. Within the placenta, discrimination of 
steroid metabolism in the foetal and maternal zones is necessary. 11βHSD1 inhibitors are 
being developed to treat Alzheimer’s disease [53], and investigators need to understand 
whether drugs reach the target brain region (e.g. hippocampus) and reduce local active 
glucocorticoid levels in these specific sites. AV sampling across the tissue will not reveal the 
hormonal milieu in sub regions and analysis of tissue homogenates loses regional information 
[54], although dissection of larger sub-regions within tissues is possible as achieved with 
human placenta [55;56] in combination with LC-MS/MS. MS imaging (MSI) [57] has 
recently joined the analytical armamentarium to address these complex questions. Here 
steroids are measured in intact tissue sections, rather than fluids or tissue homogenates. Laser 
beams are rastered across a tissue surface collecting ionised species from distinct subzones. 
Collation of the species detected allows tissue maps of analytes to be reconstructed. 
 
Cobice et al [58] recently applied this approach to visualise glucocorticoids in brain and 
address whether an 11βHSD1 inhibitor could suppress the active steroid levels within the 
hippocampus (Figure 3). Measuring steroids in sections in their native state was not possible 
due to poor ionisation and extensive ion suppression by the matrix, but the steroid signal 
could be distinguished from background following derivatisation with Girard T reagent. This 
technique is exciting, although not yet mainstream, as it requires highly specialised accurate 
mass MS instruments. Great care must be taken to prepare and store the tissue at low 
temperatures to prevent tissue degradation (compounding ion suppression problems) or 
analyte diffusion, delocalising the signal. Consideration must be taken to align the size of the 
region required to provide histologically meaningful data. Laser size is limited to ~50µm; 
indeed sampling smaller areas may generate insufficient ions for robust detection. For a 
thorough review of the technical challenges see [57]. MSI provides relative as opposed to 
absolute quantitation, but an internal standard can be applied to the tissue surface to normalise 
the signal. Imaging could be combined with tracer infusions to allow comparison of rates of 
regional regeneration of glucocorticoids.  
 
One caveat of MSI is that in the absence of chromatography, the data generated by MSI 
cannot distinguish isomeric or isobaric species. Although this has not restricted the use of 
MSI as yet in studying glucocorticoid biology, extrapolation to other steroid or sterol classes 
presents greater challenges. Girard T derivatives may be useful in the study of testosterone in 
tissues but a natural isomer DHEA forms an isobaric derivative; DHEA is of greater 
abundance in humans but believed to be biologically inert. The future may lie in ion mobility 
as an alternative separation approach. Some success has been reported for the separation of 
estrogen derivatives using ion mobility, but not as yet in conjunction with imaging.[59]. 
 
Conclusion 
MS has been pivotal in understanding the complex biochemical pathways relating to steroid 
hormone biology and its application in conjunction with in vivo physiology techniques has 
supported insightful studies of dynamic glucocorticoid activation and inactivation within 
tissues in health and disease. With continued research and development of MS 
instrumentation, the endocrine field will continue to benefit from the advancing technology 
and in the next decade we expect more specific analysis with greater application of accurate 
mass resolution. Instruments that permit introduction of biological samples in their intact state 
as opposed to extracts (e.g. liquid extraction surface analysis, DESI [57;58]) are becoming 
commercially available. However it is vital that new technologies retain the specific isomeric 
resolution afforded by GC and LC–MS (MS) to be aligned to the challenges of understanding 
vital contributions of individual steroids in endocrine research. 
 
Figure 1 
Glucocorticoids (cortisol in humans) are synthesised by the adrenal glands and released into 
the circulation under the stimulus of the hpothalamic-pituitary-adrenal axis. Within tissues 
glucocorticoids are activated and inactivated enzymatically.  CRH = corticotrophin releasing 
hormone, ACTH = adrneocorticopic hormone; HSD = hydroxysteroid dehydrogenase; CYP = 
cyotchrome P450. 
 
Figure 2 
D4-cortisol is metabolised by the enzyme 11β-hydroxysteroid dehydrogenase type 2 
(11βHSD2), losing 11α-deuterium and forming D3-cortisone. D3-cortisone is reactivated to 
D3-cortisol by reduction by 11βHSD1 and NADPH as a co-factor. All steroids have distinct 
mass transitions when assessed by liquid chromatography tandem mass spectrometry. 
 
Figure 3 
Mass spectrometry imaging of Girard T derivatives of active (corticosterone) and inactive 
(11-dehydrocorticosterone) glucocorticoids in rodent brain. Heat map showing intensity of 
signal collected by matrix assisted laser desorption ionisation with a spatial resolution of 
150µm. Data were collected using a Fourier Transform Ion Cyclotron Resonance Mass 
Spectrometer. Adapted from Cobice et al [58]. 
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